Spravato (esketamine) and ketamine are closely related, but they are not the same medication. Both belong to the same family of compounds and affect similar pathways in the brain, yet there are important differences in how they are formulated, approved, and used in clinical practice. Understanding these differences helps patients better understand why Spravato is used in structured psychiatric settings.
Understanding the Connection Between Spravato and Ketamine
Ketamine is a well-known anesthetic medication that has been used in medicine for decades. It exists as a mixture of two molecular forms, known as enantiomers. Spravato is derived from one of these forms, called esketamine.
This means Spravato is a more specific version of ketamine, designed to target certain brain receptors in a controlled and standardized way. While they are chemically related, Spravato is not simply “regular ketamine” in nasal spray form.
Key Differences in Composition
The most important difference between Spravato and ketamine lies in their chemical structure and formulation. Ketamine used in anesthesia or some off-label psychiatric settings is typically a racemic mixture, meaning it contains both forms of the molecule.
Spravato, on the other hand, contains only esketamine, which is one part of that mixture. This refined formulation allows for more targeted effects on mood-related pathways in the brain.
How They Work in the Brain
Both ketamine and Spravato influence the brain’s glutamate system, particularly NMDA receptors. This system plays a major role in mood regulation, stress response, and neural communication.
By affecting NMDA receptor activity, both treatments can promote changes in brain connectivity and support improved communication between nerve cells. These changes are associated with improvements in depressive symptoms, especially in individuals who have not responded to traditional antidepressants.
Even though the mechanism is similar, Spravato is designed and dosed specifically for psychiatric use in a controlled medical environment.
Differences in Medical Use and Approval
Another major difference is how each treatment is regulated and prescribed.
Ketamine is FDA-approved as an anesthetic and is sometimes used off-label for depression in certain clinics. Spravato, however, is specifically FDA-approved for treatment-resistant depression and must be administered under a structured safety program.
This approval means Spravato is used with strict guidelines, including in-office administration and post-treatment monitoring.
At Allied Psychiatry and Mental Health, Spravato is provided in a controlled clinical setting under the supervision of Dr. Hadi Estakhri, MD to ensure patient safety and proper response tracking.
Administration and Safety Monitoring
Spravato is administered as a nasal spray in a certified healthcare setting. After administration, patients are monitored for a period of time due to potential side effects such as dissociation, dizziness, or temporary changes in perception.
Ketamine treatments, depending on the setting, may be delivered intravenously, intramuscularly, or through other routes, often with different monitoring protocols depending on the clinic.
The structured monitoring requirement for Spravato is one of the key reasons it is considered a regulated psychiatric treatment rather than a general off-label therapy.
Why the Distinction Matters for Patients
Although Spravato and ketamine are related, the distinction matters because it affects safety, dosing, and clinical oversight. Spravato is specifically developed for depression treatment with standardized dosing and controlled administration.
This helps ensure consistency in treatment response and reduces variability in how the medication is used across patients.
Conclusion
Spravato is not the same as ketamine, but it is closely related. It is a purified form of ketamine called esketamine, developed specifically for the treatment of depression under medical supervision. While both work on similar brain pathways, Spravato is formulated, approved, and administered in a more controlled and specialized way.
At Allied Psychiatry and Mental Health, Dr. Hadi Estakhri, MD uses Spravato as part of a structured treatment plan for patients who need advanced support for depression, ensuring safe and monitored care throughout the process.
About the Author
Hadi Estakhri, MD - Founder
May 13, 2026
